A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
Public ClinicalTrials.gov record NCT04877288. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
Study identification
- NCT ID
- NCT04877288
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 102 participants
Conditions and interventions
Conditions
Interventions
- Belatacept Biological
- Tacrolimus Drug
- Cyclosporine A Drug
- Mycophenolate Mofetil Drug
- Enteric Coated Mycophenolate Sodium Drug
- Corticosteroids Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 12 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 20, 2021
- Primary completion
- Dec 29, 2032
- Completion
- Jun 29, 2034
- Last update posted
- Jun 24, 2026
2021 – 2034
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0042 | Birmingham | Alabama | 35233 | Withdrawn |
| Local Institution - 0041 | Los Angeles | California | 90095 | Withdrawn |
| Local Institution - 0014 | Washington D.C. | District of Columbia | 20010 | Withdrawn |
| Local Institution - 0022 | Hollywood | Florida | 33021 | Withdrawn |
| Local Institution - 0045 | Miami | Florida | 33136 | Withdrawn |
| Local Institution - 0049 | Atlanta | Georgia | 30322 | Withdrawn |
| Local Institution - 0033 | Chicago | Illinois | 60611 | Withdrawn |
| Local Institution - 0017 | Baltimore | Maryland | 21287 | Withdrawn |
| Local Institution - 0044 | Boston | Massachusetts | 02115 | Withdrawn |
| Local Institution - 0043 | St Louis | Missouri | 63110 | Withdrawn |
| Local Institution - 0024 | Durham | North Carolina | 27710 | Withdrawn |
| Local Institution - 0025 | Cincinnati | Ohio | 45229 | Withdrawn |
| Local Institution - 0048 | Cleveland | Ohio | 44124 | Withdrawn |
| Local Institution - 0052 | Portland | Oregon | 97239 | Withdrawn |
| Local Institution - 0038 | Seattle | Washington | 98105 | Withdrawn |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04877288, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 24, 2026 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04877288 live on ClinicalTrials.gov.